Compare General Dynamics Corporation (GD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Sana Biotechnology Inc — how do they compare? General Dynamics Corporation trades at $392 (market cap $106.03B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: General Dynamics Corporation is far larger — about 93.8× Sana Biotechnology Inc's market cap, and General Dynamics Corporation pays a 1.62% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| GD | SANA | |
|---|---|---|
Market Cap | $106.03B | $1.13B |
Sector | Industrials | Health |
52-Week High | $395.97 | $5.92 |
52-Week Low | $312.53 | $2.68 |
Enterprise Value | $111.17B | $1.05B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $394.17, down 0.45% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating estimates, revenue growth to $52.55B in 2025, and improving profit margins. Recent contract wins include a $29.5B submarine award and a $1.3B Army cybersecurity contract, supporting the $136.5B backlog.
Outlook remains positive with analyst consensus target of $427.40 representing 8.4% upside potential. Key opportunities include defense budget tailwinds and strong contract pipeline, while risks involve valuation concerns at 23.9 P/E and execution challenges on large government contracts. The stock offers steady dividend payments with recent $1.59 quarterly declaration.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
